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Background: Cardiac troponin (cTn) is an emerging prognostic biomarker in pts with stable ischemic heart disease (SIHD). New high-sensitivity 
assays are able to measure cTn at levels undetectable by current commercial assays. We assessed the prognostic performance of serial 
measurements of an investigational high-sensitivity cTnI assay in pts with SIHD.
methods: We measured cTnI (Erenna, Singulex, 99th%ile 9 pg/mL,‘sm-TnI’) at 30 days and 4 mos in 2,664 pts who had been stable through 4 
mos without recurrent events after an acute coronary syndrome in PROVE IT-TIMI 22. Our primary endpoint was cardiovascular death (CVD) or heart 
failure (HF). Pts were followed for 2 years on average.
results: Pts with ‘high’ (≥9 pg/mL) sm-TnI at 4 mos were at increased risk of CVD/HF at 2 years (5.1% v. 2.0%, p<0.001; HR 2.62, CI 1.69-4.06) 
including a higher rate of CVD (1.4% v. 0.4%, p=0.01; HR 2.80, CI 1.23-6.38) and HF (3.9% v. 1.6%, p<0.001; HR 2.63, CI 1.60-4.30), individually. 
Measured in series, pts with a newly elevated sm-TnI at 4 mos (‘low-high’) were at highest risk of CVD/HF at 2 years (6.0%; HR 3.28, CI 1.44-7.44, 
Figure). Pts with elevated sm-TnI at both follow-up lab draws also had an increased risk of CVD/HF (‘high-high’; 4.7%, HR 2.95, CI 1.73-5.02), as did 
those with sm-TnI elevated at 30 days but within normal range at 4 mos (‘high-low’; 3.3%, HR 2.16, CI 1.13-4.13, Figure).
conclusions: Serial measurements of cTnI using an investigational high-sensitivity assay enhanced risk stratification for CVD/HF in pts with SIHD. 
